Skye Bioscience Inc. (SKYE)
NASDAQ: SKYEHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SKYE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.44M
- EPS (TTM)
- -$10.16
- Dividend yield
- None
- 52-week range
- 1.50 – 14.08
- Day range
- 1.63 – 1.68
- Volume / Avg
- 20.86K / 89.28K
- Beta
- —
- Shares outstanding
- 4.43M
- Next earnings
- Nov 9, 2026
52-week range
SKYE stock today
On Oct 8, SKYE ended the session at $1.68, adding $0.03 (1.82%), versus the S&P 500's 0.47% decline. Trading was light, with 20.86K shares changing hands, about 23% of the average daily volume. At this level, SKYE sits near the bottom of its 52-week range of $1.50 to $14.08: 88.1% below the high and 12.0% above the low.
Skye Bioscience has posted a net loss over the last twelve months (EPS of -$10.16), so its P/E ratio is not meaningful. Skye Bioscience's next earnings report is expected on Nov 9, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Skye Bioscience
Company profileSkye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Punit S. Dhillon B.A.
- Headquarters
- San Diego, CA
- Employees
- 2
- Website
- skyebioscience.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$68.00+3947.62%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 9, 2026
Skye Bioscience peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRAWTraws Pharma Inc. | 0.4803 | +0.27% | $7.38M | vs SKYE |
| AIMAIM ImmunoTech Inc. | 0.1796 | -1.75% | $7.17M | vs SKYE |
| CURXCuranex Pharmaceuticals Inc | 4.76 | -0.94% | $7.46M | vs SKYE |
| CLGNCollPlant Biotechnologies Ltd | 3.97 | +14.74% | $7.51M | vs SKYE |
| SNGXSoligenix Inc. | 0.3466 | -1.95% | $7.54M | vs SKYE |
| LGVNLongeveron Inc. Class A | 2.37 | -2.87% | $7.56M | vs SKYE |
| BOLTBolt Biotherapeutics Inc. | 3.65 | +1.39% | $7.03M | vs SKYE |
| APREAprea Therapeutics Inc. | 0.5582 | -7.74% | $7.03M | vs SKYE |
Indexes, lists and sector
Appears in lists
Skye Bioscience stock FAQ
What is Skye Bioscience's stock price today?
SKYE last traded at $1.68 as of Oct 8, 4:00 PM EDT, up 1.82% on the day. Prices are delayed at least 15 minutes.
When is Skye Bioscience's next earnings date?
Skye Bioscience is expected to report earnings on Monday, November 9, 2026.
Who is Skye Bioscience's CEO?
Mr. Punit S. Dhillon B.A. is the chief executive officer of Skye Bioscience Inc., which has about 2 employees.
What is the SKYE 52-week high?
The 52-week high for SKYE is $14.08 and the 52-week low is $1.50. The stock is currently 88.1% below its high.